Most recently Sotatercept has been shown to effectively re-balance TGFb/BMPR2 signaling in preclinical models of PH as well as in a phase II PAH trial and was able to improve pulmonary vascular resistance in PAH patients on background PAH therapy (NEJM 2021), validating the approach of restoring normal BMPR2 signaling as a therapeutic approach in PAH. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.